Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation

• Published in: Oncogene 2022-04, Vol.41 (18), p.2571-2586
• Main Authors: Sala, Margaux, Allain, Nathalie, Moreau, Mélanie, Jabouille, Arnaud, Henriet, Elodie, Abou-Hammoud, Aya, Uguen, Arnaud, Di-Tommaso, Sylvaine, Dourthe, Cyril, Raymond, Anne-Aurélie, Dupuy, Jean-William, Gerard, Emilie, Dugot-Senant, Nathalie, Rousseau, Benoit, Merlio, Jean-Phillipe, Pham-Ledart, Anne, Vergier, Béatrice, Tartare-Deckert, Sophie, Moreau, Violaine, Saltel, Frédéric
• Format: Article
• Language: English
• Subjects: 13/1; 13/106; 13/109; 13/2; 13/51; 13/89; 13/95; 14/19; 14/34; 14/35; 631/67/1059/2326; 631/67/1813/1634; 631/80/86; 64/60; 82/51; 82/58; Actin; Apoptosis; Axl protein; Cell Biology; Cell Line, Tumor; Cell Proliferation; Cell Proliferation - genetics; Cytoskeleton; Discoidin Domain Receptor 2; Discoidin Domain Receptor 2 - genetics; Drug Resistance, Neoplasm; Drug Resistance, Neoplasm - genetics; Genotype & phenotype; Human Genetics; Humans; Internal Medicine; Kinases; Life Sciences; MAP kinase; Medicine; Medicine & Public Health; Melanoma; Melanoma - drug therapy; Melanoma - genetics; Melanoma - metabolism; Mesenchyme; Metastases; Oncology; Phenotype; Phenotypes; Protein Kinase Inhibitors; Protein Kinase Inhibitors - pharmacology; Proto-Oncogene Proteins B-raf; RhoA protein; Tumors
• ISSN: 0950-9232; 1476-5594
• DOI: 10.1038/s41388-022-02266-1

Combined therapy with anti-BRAF plus anti-MEK is currently used as first-line treatment of patients with metastatic melanomas harboring the somatic BRAF V600E mutation. However, the main issue with targeted therapy is the acquisition of tumor cell resistance. In a majority of resistant melanoma cells, the resistant process consists in epithelial-to-mesenchymal transition (EMT). This process called phenotype switching makes melanoma cells more invasive. Its signature is characterized by MITF low, AXL high, and actin cytoskeleton reorganization through RhoA activation. In parallel of this phenotype switching phase, the resistant cells exhibit an anarchic cell proliferation due to hyper-activation of the MAP kinase pathway. We show that a majority of human melanoma overexpress discoidin domain receptor 2 (DDR2) after treatment. The same result was found in resistant cell lines presenting phenotype switching compared to the corresponding sensitive cell lines. We demonstrate that DDR2 inhibition induces a decrease in AXL expression and reduces stress fiber formation in resistant melanoma cell lines. In this phenotype switching context, we report that DDR2 control cell and tumor proliferation through the MAP kinase pathway in resistant cells in vitro and in vivo. Therefore, inhibition of DDR2 could be a new and promising strategy for countering this resistance mechanism.